Maternal And Neonatal Outcomes Associated With Preimplantation Genetic Testing In Ivf Singleton Live Births

Despite its widespread use, data regarding the impact of preimplantation genetic testing (PGT) on pregnancy outcomes are limited. We set out to determine whether PGT is associated with adverse maternal or neonatal outcomes in singleton in vitro fertilization (IVF) pregnancies. Retrospective cohort of singleton live births conceived by IVF within a university health system and delivered between January 2014 and August 2019. Patients with missing outcome data were excluded. Adverse maternal outcomes, i.e. hypertensive disorders of pregnancy, abnormal placentation, preterm birth, and adverse neonatal outcomes were compared between two groups: patients who had a transfer of a PGT screened euploid embryo versus transfer of an untested embryo. Statistical analysis included use of Chi-square and Wilcoxon rank sum tests, as well as multivariate backwards-stepwise logistic regression, with significance defined as P value < 0.05. Data was presented as adjusted Odds Ratios (OR) with 95% confidence intervals (CI). Of the 1,015 live births, 496 (48.9%) underwent PGT prior to conception and 519 (51.1%) did not. A subset of baseline characteristics, such as race or ethnic group, infertility diagnosis, egg source, and cycle type, were significantly different between the two groups (Table 1). After adjusting for potential confounders, there was no significant difference between the two groups with respect to adverse maternal or neonatal outcomes (Table 2). Our data suggest that IVF with PGT is not associated with an increased risk of adverse maternal or neonatal outcomes compared to IVF without PGT. Specifically, the rates of placental disorders such as hypertensive disorders of pregnancy, fetal growth restriction and abnormal placentation were similar between the two groups. Such data may provide reassurance to couples when planning fertility treatments.View Large Image Figure ViewerDownload Hi-res image Download (PPT)